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Abstract. Combretastatin A-4 (CA-4) is a naturally occur-
ring microtubular-destabilising agent that possesses potent 
anti-tumour and anti-vascular properties both in vitro and 
in vivo. Clinical trials to date indicate that its water-soluble 
prodrug, combretastatin A-4 phosphate (CA-4P), is well toler-
ated at therapeutically useful doses. However, the stilbenoid 
structure of CA-4, consisting of two phenyl rings linked by an 
ethylene bridge, renders the compound readily susceptible to 
isomerisation from its biologically active cis-conformation to 
its more thermodynamically stable but inactive trans-isomer. 
To circumvent this problem, we synthesised a series of cis-
restricted CA-4 analogues. Replacement of the ethylene bridge 
with a 1,4-diaryl-2-azetidinone (β-lactam) ring provided a rigid 
scaffold thus preventing cis-trans isomerisation. We previ-
ously documented that these tubulin-depolymerising β-lactam 
compounds potently induced cell cycle arrest and apoptosis in 
a variety of cancerous cell lines (including those displaying 
multidrug resistance) and ex vivo patient samples, whilst 
exerting only minimal toxicity to normal cells. The purpose of 
this study was to elucidate the effect of the β-lactam compounds 
on both tumour vascularisation and tumour cell migration, two 
critical elements that occur during the growth and metastatic 
progression of tumours. We established that two representa-
tive β-lactam compounds, CA-104 and CA-432, exerted both 
anti-endothelial effects [G2/M arrest and apoptosis of primary 
human umbilical vein endothelial cells (HUVECs)] and 
anti-angiogenic effects [inhibition of HUVEC migration and 
differentiation and reduced vascular endothelial growth factor 
(VEGF) release from MDA-MB-231 breast adenocarcinoma 
cells]. In addition, we established that lead analogue, CA-432, 
abrogated the migration of MDA-MB-231 cells indicating an 
anti-metastatic function for these compounds. In summary, 
our results to date collectively indicate that these cis-restricted 
β-lactam CA-4 analogues may prove to be useful alternatives 
to CA-4 in the treatment of cancer but with the added advan-
tage of improved stability of the cis-isomer.
Introduction
The combretastatins are a family of stilbenoids, some of 
which possess potent anti-tumour and anti-vascular proper-
ties. Originally isolated from the bark of the South African 
bush willow tree Combretum caffrum, these naturally occur-
ring stilbenes consist of two phenyl rings, the A-ring and 
B-ring, linked by an ethylene bridge (1). The most extensively 
studied member of the family, combretastatin A-4 (CA-4) is 
well documented to function as a microtubule targeting agent 
(2). Microtubules are dynamic filaments composed of α- and 
β-tubulin heterodimers that are key components of the mitotic 
spindle. Thus, agents that interfere with microtubule dynamics 
perturb mitotic cell division (3). CA-4 is a tubulin depoly-
merising agent that interacts with β-tubulin at or close to its 
colchicine binding site leading to the destabilisation of micro-
tubules and preventing the formation of the mitotic spindle 
and hence results in mitotic arrest and subsequently cell death 
of tumour cells (2,4,5). Its water-soluble phosphate prodrug 
combretastatin A-4 phosphate (CA-4P) or fosbretabulin is 
readily cleaved in vivo by non-specific endogenous phospha-
tases to yield active CA-4 (6). 
CA-4P induced rapid selective tumour vascular shutdown 
and tumour regression in both subcutaneous and orthotopical 
mouse tumour models at concentrations well below the 
maximum tolerated dose (7,8). It also reduced tumour blood 
flow in phase I clinical trials at well tolerated doses (9,10). 
Consequently, CA-4P has recently completed numerous 
phase II clinical trials including trials for the use of CA-4P in 
the treatment of advanced anaplastic thyroid cancer (11), CA-4P 
in combination with paclitaxel and/or carboplatin in the treat-
ment of advanced solid tumours and combinations of CA-4P, 
anti-angiogenic bevacizumab, carboplatin and paclitaxel for 
chemotherapy naive non-small cell lung cancer (12). In addi-
tion, phase II trials for the treatment of neovascular age-related 
macular degeneration and polypoidal choroidal vasculopathy 
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have also been undertaken (12). CA-4P in combination with 
bevacizumab is currently recruiting for phase II trials for 
reoccurring or persistent tumours of the ovarian epithelial, 
fallopian tube or peritoneal cavity and is about to enter phase I 
trials for the treatment of recurrent high grade gliomas (12).
While in vitro studies have demonstrated the anti-prolif-
erative and cytotoxic effects of CA-4 on endothelial cells 
(7,13), the rapid vascular changes observed in vivo occur 
too early to be attributed to endothelial cell death. The rapid 
response of endothelial cells to CA-4 is thought to involve 
disruption to interphase microtubules triggering rapid remod-
elling of the actin cytoskeleton, assembly of actin stress fibres, 
actinomyosin contractility, formation of focal adhesions and 
disruption of cell-cell junctions (14).
Both the success and the limitations of CA-4 lie in its stil-
bene structure, illustrated in Fig. 1. Only the cis-configuration 
of CA-4 is biologically active (15). The spatial arrangement 
between its 3,4,5-trimethyloxyphenyl A-ring and 3-hydroxy-
4-methoxyphenyl B-ring are crucial to its functionality and 
ability to interact with tubulin (15-17). However, the cis-isomer 
is intrinsically unstable and readily isomerises to the more 
thermodynamically stable but inactive trans-configuration 
(15). Cis-trans isomerisation can be triggered by heat, light and 
protic media thus lowering the therapeutic efficacy of the agent.
We recently synthesised a series of CA-4 analogues 
that have been stabilised in their cis-configuration by the 
replacement of the usual ethylene bridge of CA-4 with a 
1,4-diaryl-2-azetidinone (β-lactam) ring (18,19). The β-lactam 
ring provided a scaffold structure that retained a similar 
spatial arrangement between the two phenyl rings as the 
cis-conformation of CA-4. These compounds were either 
unsubstituted at position C-3 of the β-lactam ring or substituted 
with methyl groups (18) or aryl rings (19). Molecular docking 
studies indicated that representative compounds were capable 
of interacting with tubulin with similar positioning to CA-4. 
Several compounds inhibited tubulin polymerisation in vitro 
and demonstrated potent anti-mitotic potential in a selec-
tion of tumour cell lines derived of diverse origin including 
leukaemia, breast, non-small cell lung, colon, CNS, melanoma, 
ovarian, cervical, renal and prostate cancers (18-21). 
Furthermore, low nanomolar concentrations of representa-
tive compounds caused tubulin depolymerisation, resulting in 
loss of cell viability mediated by G2M arrest and apoptosis 
of breast carcinoma ER-positive MCF-7 and ER-negative 
MDA-MB-231 cells whilst exerting no significant cytotoxicity 
to normal murine breast epithelial cells (IC50 >10 mM) (19). 
Significantly, lead compound CA-432 also induced potent 
anti-tubulin, anti-proliferative and anti-mitotic effects in 
human promyelocytic leukaemia HL60 cells expressing multi-
drug-resistant transporters P-glycoprotein or breast cancer 
resistance protein (BCRP) and in ovarian carcinoma A2780 
cells also expressing P-glycoprotein. Molecular docking 
studies supported the notion that CA-432 was not a substrate 
for P-glycoprotein. Furthermore, CA-432 induced apoptosis 
in ex vivo samples from chronic myeloid leukaemia (CML) 
patients including those displaying resistance to imatinib 
mesylate, the frontline treatment for CML (20).
While our studies to date demonstrate the cytotoxic effects 
of these cis-restricted β-lactam CA-4 analogues on a variety 
of tumour cells derived from both the haematopoietic system 
and from solid tumours, we have not investigated their effects 
on endothelial cells. Tumour vascularisation is essential for 
tumour growth and metastases. Therefore, the purpose of this 
study was to examine the anti-vascular, anti-angiogenic and 
anti-metastatic properties of these compounds through a series 
of in vitro tests. We selected two lead analogues, CA-104 and 
CA-432, for this purpose (Fig. 1). CA-104 was unsubstituted 
at position C-3 of the β-lactam ring (18), while, CA-432 was 
substituted with a 4-(3-hydroxy-4-methoxyaryl ring) (19). We 
established that both compounds displayed anti-endothelial 
properties in vitro. They induced tubulin depolymerisation in 
primary human umbilical vein endothelial cells (HUVECs). 
This effect was associated with a loss in endothelial cell 
viability mediated by G2M arrest and apoptosis. We also 
demonstrated both direct and indirect anti-angiogenic events. 
Both compounds prevented migration and in vitro capillary 
tubule formation by HUVECs whilst lead compound, CA-432, 
reduced the release of VEGF from breast adenocarcinoma 
MDA-MB-231 cells. Finally, we established that CA-432 
abrogated migration of these highly metastatic MDA-MB-231 
cells. Of note, these anti-angiogenic and anti-metastatic events 
preceded any cytotoxic effects attributed to the β-lactam 
analogues.
These findings indicate a novel function for these β-lactam 
CA-4 analogues. Our findings collectively demonstrated that 
these rigid cis-restricted analogues exhibited anti-tumour, 
anti-vascular, anti-angiogenic and anti-metastatic properties 
with minimal toxicity to normal cells. Replacement of the 
ethylene bridge with a β-lactam ring yielded compounds that 
retained the in vitro functionality of CA-4 but with the addi-
tional advantage of conformational stability.
Materials and methods
Unless otherwise stated, chemicals were obtained from 
Sigma-Aldrich (Poole, Dorset, UK) and tissue culture vessels 
were sourced from Greiner Bio-One GmbH (Frickenhausen, 
Germany).
Cell culture. Pooled primary human umbilical vein endothe-
lial cells (HUVECs) and their associated reagents were all 
obtained from Cascade Biologics (Invitrogen, Carlsbad, CA, 
USA). HUVECs were maintained between passages 1-4 in 
Medium 200 supplemented with LSGS (low serum growth 
factor supplement) and utilised for experiments at passage 4. 
Human breast adenocarcinoma MDA-MB-231 cells (ATCC, 
Manassas, VA, USA) were maintained in Dulbecco's modified 
Eagle's medium (DMEM) enhanced with GlutaMAX-I and 
supplemented with 10% foetal bovine serum, 50 U/ml peni-
cillin and 50 µg/ml streptomycin (all purchased from Gibco, 
Invitrogen). Cells were maintained in a humidified incubator at 
37˚C in 5% CO2 and were subcultured by trypsinisation upon 
reaching 70-80% confluency.
Reagents. Two representative cis-restricted β-lactam 
com bretastatin A-4 analogues were used in this study. Their 
structures are illustrated in Fig. 1. Analogue 4-(3-hydroxy-
4-methoxyphenyl)-1-(3,4,5-trimethoxyphenyl)azetidin-2-one 
(CA-104) was synthesised as previously described in Carr et al 
(18) where this compound was referred to as compound 12d. 
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Analogue 4-(3-hydroxy-4-methoxyphenyl)-3-phenyl-1-
(3,4,5-trime thoxyphenyl)azetidin-2-one (CA-432) was 
synthesised as described in O'Boyle et al (19) where it 
was referred to as compound 35. The analogues were 
dissolved in ethanol and stored in the dark at -20˚C. Human 
recombinant VEGF165 (R&D Systems Inc., Minneapolis, 
MN, USA) was reconstituted to 1 µg/ml in 0.1% (w/v) 
bovine serum albumin (BSA) and also stored at -20˚C.
Cell viability assays. HUVECs (20,000 cells/well) or 
MDA-MB-231 cells (12,000 cells/well) were grown on 
96-well plates. The cells were treated (24 h post-seeding) 
with a range of concentrations of the analogues for up to 
72 h. Cellular metabolic activity and hence cell viability was 
monitored using AlamarBlue™ dye (BioSource, Invitrogen) 
which was added to each well [final concentration of 10% 
(v/v)] and incubated at 37˚C. The change from an oxidized 
indigo blue non-fluorescent state to a fluorescent pink state in 
the reduced environment of living cells was measured at an 
excitation wavelength of 544 nm and an emission wavelength 
of 590 nm using a SpectraMax Gemini spectrofluorometric 
microtiter well plate reader (Molecular Devices, Sunnyvale, 
CA, USA). The results were expressed as the percentage of 
cell viability relative to the vehicle-treated control cells 
(100%). Dose-response curves were plotted, and IC50 values 
(the concentration of compound resulting in 50% reduction in 
cell viability) were obtained using Prism GraphPad 4.
Determination of DNA content. Following treatment, 
HUVECs were harvested by centrifugation at 800 x g for 
10 min. Cell pellets were resuspended in 200 µl PBS and fixed 
by a drop-wise addition of 2 ml of ice-cold 70% (v/v) ethanol/
PBS while gently vortexing. Following overnight fixation at 
-20˚C the cells were again centrifuged to remove the ethanol 
and resuspended in PBS supplemented with 0.5 mg/ml RNase 
A and 0.15 mg/ml propidium iodide. Cells were incubated in 
the dark at 37˚C for 30 min. The fluorescence emitted from 
the propidium iodide was measured on a linear scale using 
a FACSCalibur flow cytometer (Becton Dickinson, San Jose, 
CA, USA). Data collections (10,000 events per sample) were 
gated to exclude cell debris and cell aggregates. Fluorescence 
was proportional to the amount of DNA present in each entity 
and therefore indicated the stage of the cell cycle it was in. 
Cells in G0/G1 were diploid (2N DNA content), cells in G2/M 
were tetraploid (4N DNA content), cells in the S phase had 
DNA contents between 2N and 4N, while apoptotic cells were 
hypoploid and contained <2N DNA. All data were recorded 
and analysed using the CellQuest software (Becton Dickinson).
Microtubule staining. HUVECs (60,000 cells/chamber) 
were cultured on BD Falcon™ 4-chamber glass slides (BD 
Biosciences, Bedford, MA, USA) for 24 h. Following treat-
ment for 16 h, the cells were fixed in 100% methanol at -20˚C 
and the microtubular network was detected by indirect immu-
nofluorescence as previously described (22). Briefly, the slides 
were sequentially incubated in a blocking solution [5% (w/v) 
BSA/0.1% (v/v) Triton X-100/PBS], monoclonal anti-α-tubulin 
antibodies (Merck Biosciences, Nottingham, UK), fluorescein 
isothiocyanate (FITC)-conjugated rabbit anti-mouse anti-
bodies (DakoCytomation, Glostrup, Denmark) and finally 
0.2 µg/ml propidium iodide (to stain DNA). An anti-quenching 
solution (2 µg/ml p-phenylenediamine in 50:50 glycerol:PBS) 
was applied to the surface of the slides and coverslips were 
mounted. The organisation of the microtubule network 
(green) and the cellular DNA (red) was visualised under a x60 
oil-immersion lens using an Olympus IX81 fluorescent micro-
scope (Olympus Corporation, Tokyo, Japan).
Endothelial cell migration. Costar® 8 µM-pore Transwell 
inserts (Corning Incorporated, Corning, NY, USA) were 
coated overnight at 4˚C with 10 µg/ml human fibronectin. 
HUVECs (10,000 cells in 100 µl medium) were seeded onto 
the transwell inserts, placed in 24-well plates containing 0.6 ml 
medium and incubated for 1 h. HUVEC migration was stimu-
lated by addition of 10 ng/ml VEGF to the lower well. Vehicle 
or the indicated analogues were also added to the lower wells. 
After a period of 6 h the upper surfaces of the inserts were 
swabbed to remove non-migrated cells. Filters were incubated 
overnight in a solution containing 0.5% toluidine blue O and 
0.5% sodium tetraborate to stain the migrated cells. Following 
solubilisation of the cells using 0.2% (w/v) SDS in 20 mM 
Tris-HCl, pH 7.7, the absorbance was determined at 650 nm in 
a spectrophotometer (Molecular Devices).
In vitro tubule formation. HUVECs (1.5x106 cells/well), were 
incubated on BD Biocoat™ Matrigel™-coated 6-well plates (BD 
Biosciences) for 6 h in the presence of vehicle or the indicated 
compounds. The ability of the HUVECs to spontaneously form 
capillary-like tubules on the Matrigel (basement membrane 
matrix preparation) was photographed under a Nikon Eclipse 
TE300 phase contrast microscope (Nikon Instruments Inc., 
Melville, NY, USA) at a magnification of x100.
Detection of VEGF release. MDA-MB-231 cells (60,000 cells/
cm2) were grown for 24 h, then washed in PBS and incubated in 
Figure 1. Chemical structures of combretastatin A-4 and its novel cis-restricted 
β-lactam analogues, CA-104 and CA-432.
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a low serum environment [DMEM supplemented with 1% (v/v) 
FBS] in the presence or absence of lead analogue CA-432 for 
6 h. The conditioned medium was then centrifuged at 400 x g 
and the supernatants were collected while the cells were lysed 
in sample buffer [62.5 mM Tris (pH 6.8), 2% (w/v) SDS, 10% 
(v/v) glycerol], sonicated briefly and denatured by boiling for 
3 min. The concentration of VEGF in the supernatants was 
determined by ELISA using a Quantikine Human VEGF 
Immunoassay kit (R&D Systems Inc.) in accordance with 
manufacturer's handbook. The colour intensity (proportional 
to the concentration of VEGF) was determined by measuring 
the absorbance in a SpectraMax 340PC spectrophotometer 
(Molecular Devices) at wavelength 450 nm with correction 
at 540 nm. The readings were normalised to account for 
the total protein content of the cells which was determined 
from an aliquot of cell lysate using a BCA protein assay kit 
(Pierce, Thermo Fisher Scientific Inc., Rockford, IL, USA) in 
accordance with the manufacturer's instructions. Normalised 
VEGF-release was then expressed as a percentage of release 
from vehicle-treated control cells (100%).
Tumour cell migration. MDA-MB-231 cells were seeded 
at a density of 25,000 cells/well onto 24-well Falcon migra-
tion inserts (8-µm pore size) (BD Biosciences) in serum-free 
medium. Inserts were placed into Falcon companion plates 
containing DMEM supplemented with 20% FBS in the pres-
ence or absence of CA-432. Following 6 h of incubation, 
the upper surfaces of the inserts were swabbed to remove 
non-migrated cells. Migrated cells on the underside of the 
membrane were fixed in methanol, stained with Mayer's hema-
toxylin, dehydrated in methanol and mounted on a glass slide. 
The cells in 5 fields at x10 magnification were counted.
Statistical analysis. Results were presented as mean ± SEM. 
Statistical analysis of the experimental data was performed 
using the computer program Prism GraphPad 4. P-values were 
determined using a paired two-tailed Student's t-test. A value 
of P<0.05 was considered to be statistically significant.
Results
cis-restricted β-lactam combretastatin A-4 analogues, 
CA-104 and CA-432, reduce endothelial cell viability. To 
determine the effect of cis-restricted β-lactam CA-4 analogues 
on endothelial cell viability, we tested a range of concentra-
tions of the representative analogues, CA-104 and CA-432, on 
primary HUVECs for 72 h. We established that both agents led 
to a reduction in the metabolic activity and hence viability of 
HUVECs, with respective IC50 values for CA-104 and CA-432 
of 24.97 and 4.00 nM (Fig. 2). From these IC50 values, it was 
deduced that analogue CA-432 was a more potent inhibitor of 
endothelial cell viability than CA-104. The concentrations of 
CA-104 and CA-432 used for the rest of this study were chosen 
to reflect the values obtained from this cell viability assay.
CA-104 and CA-432 induce G2/M arrest and apoptosis in 
endothelial cells. Cell cycle profiles were examined to define 
the mechanisms underlying the reduction in endothelial cell 
viability following exposure to CA-104 and CA-432. HUVECs 
were treated with vehicle [0.5% (v/v) ethanol], CA-104 
(0.01-1 µM) or CA-432 (1-100 nM) for 24 h. Subsequently, 
their DNA was fluorescently stained with propidium iodide 
and analysed by flow cytometry. Examination of their DNA 
profiles indicated that both CA-104 and CA-432 induced 
a dose-dependent increase in the percentage of HUVECs 
with 4N DNA content compared to vehicle-treated cells. 
Approximately 20% of HUVECs treated with the vehicle alone 
displayed tetraploid DNA contents compared to 38.1±1.5% 
(P=0.0063) or 37.0±1.8% (P=0.0027) of the HUVECs treated 
with CA-104 (100 nM) or CA-432 (50 nM) respectively 
(Fig. 3A and B). These statistically significant increases in 4N 
DNA content indicated that the compounds induced arrest in 
the G2/M phase of the cell cycle.
G2/M arrest was accompanied by significant increases 
in the number of entities presenting with hypodiploid (<2N) 
quantities of DNA as indicated by a sub G0/G1 peak on the 
DNA profiles. While only approximately 5% of vehicle-
treated HUVECs were found to be hypodiploid, treatment 
with CA-104 (100 nM) or CA-432 (50 nM) resulted in an 
increase in the amount of hypodiploid cells to 35.0±2.6% 
(P=0.0064) or 31.4±1.3% (P=0.0019) respectively (Fig. 3C and 
D). These statistically significantly increases in hypodiploid 
cells represented an increase in the levels of apoptosis. Cell 
cycle analysis illustrated that both CA-104 and CA-432 inhib-
ited proliferation and survival of endothelial cells through the 
induction of G2/M arrest and apoptosis.
CA-104 and CA-432 cause destabilisation of the micro-
tubule network in endothelial cells. We next established the 
effect of CA-104 and CA-432 on the gross morphology of the 
micro tubular network in endothelial cells. HUVECs, grown 
on glass 4-chamber slides, were treated for 16 h with vehicle 
[0.5% (v/v) ethanol], CA-104 (100 nM) or CA-432 (50 nM). 
Immunofluorescent staining was used to detect morphological 
changes in the tubulin cytoskeleton such as alterations in 
Figure 2. Treatment with cis-restricted β-lactam combretastatin A-4 ana-
logues, CA-104 and CA-432, reduced viability of primary endothelial cells. 
HUVECs grown on 96-well plates were treated in triplicate with vehicle 
alone [1% (v/v) ethanol] or a range of concentrations of CA-104 or CA-432 
for 72 h. The cells were then incubated in 10% (v/v) AlamarBlue™ and its 
reduction to a fluorescent state was measured at excitation 544 nm and emis-
sion 590 nm using a multi-well fluorimeter. The results were expressed as the 
percentage of cell viability relative to vehicle-treated control cells (100%). 
Values represent the mean ± SEM for three separate experiments. IC50 values 
(concentration of the compound resulting in 50% reduction in cell viability) 
were obtained using Prism GraphPad 4 software.
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organisation and arrangement. In normal cells, the microtu-
bule network is organised into cytoplasmic tubulin filaments 
radiating from a central point to the periphery. HUVECs 
treated with vehicle alone (0.5% ethanol) displayed this 
typical tubulin morphology (Fig. 4). Treatment of cells with 
tubulin polymerising agents (for example, paclitaxel) results 
in a highly concentrated accumulation of filaments into dense 
peripheral bundles indicative of microtubule stabilisation. In 
contrast, exposure of cells to tubulin depolymerising agents 
(such as vincristine) results in diffuse tubule staining with no 
definition of structure caused by microtubule disassembly. 
These typical morphological changes associated with tubulin 
depolymerising agents were observed when HUVECs were 
treated with either CA-104 or CA-432 (Fig. 4).
Figure 3. CA-104 and CA-432 induce G2/M arrest and apoptosis in primary endothelial cells. HUVECs were treated with vehicle (Veh) [0.5% (v/v) ethanol] or 
the indicated concentrations of CA-104 or CA-432 for 24 h, fixed in ethanol, stained with propidium iodide and their DNA content assessed by flow cytometry. 
Analysis of data was performed using the CellQuest software. Fluorescence was proportional to the amount of DNA present in each entity and therefore 
indicated the phase of the cell cycle. Cells in the subG0/G1 phase (<2N DNA) were deemed apoptotic, while cells with 4N quantities of DNA were considered 
to be in the G2/M phase of the cell cycle. Values represent the mean ± SEM for three independent experiments. A P-value <0.05 was considered to be statically 
significant (*P<0.05, **P<0.01, ***P<0.001).
Figure 4. CA-104 and CA-432 disrupt the organisation of the microtubular network in endothelial cells. HUVECs grown on 4-chamber glass slides were 
treated with vehicle [0.5% (v/v) ethanol], CA-104 (100 nM) or CA-432 (50 nM) for 16 h. The cells were then fixed in methanol, incubated with monoclonal anti-
α-tubulin antibodies, followed by FITC-conjugated anti-mouse antibodies and then briefly stained with propidium iodide. The organisation of the microtubule 
network (green) and the cellular DNA (red) was visualised using a fluorescence microscope at a magnification of x600 (scale bar, 30 µm). Images illustrated 
are representative of three independent experiments.
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CA-104 and CA-432 reduce endothelial cell migration. 
Having established that cis-restricted β-lactam combreta-
statin A-4 derivatives altered endothelial cell function, we then 
examined their implications in angiogenic processes in vitro. 
Firstly, their effect on HUVEC migration was evaluated using 
a modified Transwell migration assay. This chemotactic model 
representative of tumour-induced endothelial cell migration 
(23) consisted of an upper and a lower chamber separated by a 
membrane. Migration of HUVECs from the upper to the lower 
chamber was stimulated by the addition of VEGF to the lower 
chamber. The effect of CA-104 (100 nM) and CA-432 (50 nM) 
on this migration was determined by their addition along with 
VEGF into the lower chamber. Migration was expressed as 
a percentage of migration by vehicle-treated cells (100%). 
Incubation for 6 h with CA-104 or CA-432 significantly 
inhibited VEGF-stimulated HUVEC migration by 70.3±4.4% 
(P=0.0039) and 74.0±1.5% (P=0.0004) respectively (Fig. 5). 
This effect preceded endothelial cell toxicity since no loss of 
HUVEC viability was evident following a 6-h treatment with 
CA-104 or CA-432 (data not shown).
CA-104 and CA-432 inhibit endothelial cell differ entiation. 
To further investigate the anti-angiogenic potential of 
CA-104 and CA-432, an endothelial tube formation assay was 
performed. The spontaneous formation of capillary-like struc-
tures by endothelial cells, when incubated on an extracellular 
basement membrane matrix preparation known as Matrigel, 
is a standard in vitro angiogenesis test (24). This process 
requires cell-matrix interaction, inter-cellular communication 
as well as cell motility and differentiation. HUVECs were 
seeded onto Matrigel in the presence of vehicle (0.5% ethanol), 
CA-104 (100 nM) or CA-432 (50 nM) for 6 h. The alignment 
of the cells on the 3D-Matrigel was assessed using a phase 
contrast microscope (Fig. 6). Vehicle-treated cells underwent 
alignment into capillary-like structures while treatment with 
either CA-104 or CA-432 reduced tubule formation. Again, as 
observed during the endothelial cell migration assay, inhibi-
tion of in vitro tubule formation preceded any cytotoxic effects 
attributed to CA-104 or CA-432.
CA-432 reduces VEGF release from breast carcinoma cells. 
The release of VEGF from tumour cells plays a key role in the 
stimulation of angiogenesis and promotion of endothelial cell 
survival (25). Therefore, we next investigated the effect of lead 
CA-4 analogue CA-432 (50 nM) on the release of VEGF from 
human breast adenocarcinoma MDA-MB-231 cells. VEGF 
release was stimulated by incubating the cells in a low serum 
environment. We found that the CA-432 (50 nM) reduced 
the release of VEGF from MDA-MB-231 cells to 80.9±1.7% 
(P=0.0080) of that released from the vehicle-treated control 
cells (Fig. 7). This event preceded any cytotoxic effects due 
to CA-432, since at 6 h post-treatment, no loss in MDA-MB-
231 cell viability was detected (data not shown). This finding 
suggested an indirect anti-angiogenic function for CA-432 
through targeting of tumour cells.
CA-432 prevents migration of breast carcinoma MDA-MB-
231 cells. The migration of tumour cells from the primary site 
is a critical step during tumour metastasis (26). We previously 
demonstrated that MDA-MB-231 cells display good migratory 
capabilities (27). Therefore, the migration of MDA-MB-231 
cells across Transwell filters in the presence of vehicle [0.5% 
(v/v) ethanol] or CA-432 (50 nM) was compared. Migration 
was expressed as a percentage of the migration of vehicle-
Figure 5. CA-104 and CA-432 significantly reduce VEGF-stimulated 
endothelial cell migration. HUVECs were seeded onto fibronectin-coated 
Transwell inserts and placed in medium-containing companion plates. 
HUVEC migration was stimulated by the addition of 10 ng/ml VEGF to the 
lower well in the presence of vehicle [0.5% (v/v) ethanol], CA-104 (100 nM) or 
CA-432 (50 nM). After 6 h, migrated cells were stained with 0.5% toulidine 
blue O and 0.5% sodium tetraborate and quantified as absorbance at 650 nm. 
The results were expressed as the percentage of migrated cells with vehicle-
treated control cells representing 100% migration and displayed as mean ± 
SEM of three experiments each carried out in duplicate. A P-value <0.05 was 
considered to be statically significant (*P<0.05, **P<0.01, ***P<0.001).
Figure 6. CA-104 and CA-432 inhibit the spontaneous in vitro tubule formation of endothelial cells. HUVECs were grown on Matrigel-coated 6-well plates for 
6 h in the presence of vehicle [0.5% (v/v) ethanol], CA-104 (100 nM) or CA-432 (50 nM). The ability of the HUVECs to form capillary-like tubules on Matrigel 
was demonstrated using a phase contrast microscope at a total magnification of x100. Images shown are representative of three independent experiments.
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treated cells (100%). Incubation for 6 h with CA-432 prevented 
MDA-MB-231 cell migration by 95.7±0.7% (P<0.0001) 
(Fig. 8). This event preceded any cytotoxic events, since 
following a 6 h treatment with CA-432, no loss in MDA-MB-
231 cell viability was detected (data not shown).
Discussion
Both tumour vascularisation and the migration of tumour cells 
are key events during the growth and metastatic progression 
of tumours. Therefore, agents that disrupt these events could 
potentially prove useful as anti-cancer therapies. Anti-vascular 
therapies can be divided into two main strategic subtypes: 
vascular-disrupting therapies that target the existing tumour 
vasculature and anti-angiogenic therapies that prevent the 
de novo synthesis of tumour blood vessels. CA-4 and its water 
soluble prodrug CA-4P fall into the first category (7) while 
micro tubule-targeting agents such as the tubulin-stabilising 
taxanes (28) and the tubulin-destabilising vinca alkaloids (29) 
form the latter group. However, between these two subtypes 
there are overlaps, as depending on the dosing strategies, anti-
angiogenic agents can also induce vascular disruption and the 
converse is also true (30). Therefore, the in vitro assays used 
to detect both strategies are similar. Anti-vascular therapies 
maximise their effects on the tumour vasculature while 
minimising damage to the systemic vasculature system by 
exploiting the fundamental differences between the normal 
mature vasculature and the immature tumour vasculature 
which tends to be disorganised, leaky and poorly associated 
with perivascular cells (31). 
Endothelial cells are desirable targets for cancer therapies 
due to accessibility and genetic stability and unlike tumour 
cells, they do not readily acquire drug resistance (32). Hence, 
anti-vascular drugs can cause tumour regression even in 
drug-resistant tumours. For example, anti-tumour activity 
was reported with docetaxel in a xenograft tumour that had 
been established by inoculating mice with docetaxel-resistant 
cancer cells, an effect that was attributed to the anti-angiogenic 
actions of docetaxel (33). After tumour vascularisation, several 
key events are critical for progression of a tumour to a meta-
static phenotype. These events include migration of tumour 
cells from the primary site into the blood/lymph system 
followed by their invasion into a different site to begin the 
process of angiogenesis and the growth of a secondary tumour 
(26). Therefore, agents which target either the tumour vascu-
lature or any of the steps that occur during tumour metastasis 
are potentially useful anticancer therapies, with agents that 
target both events the most desirable.
Naturally occurring stilbene, CA-4, is a potent inhibitor of 
tubulin polymerisation that displays potent anti-mitotic activi-
ties in both cancer and endothelial cells (2,4,5,7). In vivo, its 
water-soluble prodrug, CA-4P, induces a rapid and selective 
shutdown of tumour blood flow and subsequently tumour 
regression (7,8) and thus the compound is currently undergoing 
clinical trials as a vascular-disrupting agent. The therapeutic 
efficacy of CA-4 is limited by its intrinsic instability rendering 
it readily isomerisable to its inactive trans-conformation 
(15-17). Therefore, non-isomerisable CA-4 analogues have 
been developed to provide more stable alternatives to CA-4. 
Approaches to prevent isomerisation have included the 
replacement of the cis-double bond in CA-4 with heterocyclic 
rings such as tetrazole, imidazole and benzoxepin (34-36). 
We previously developed and patented a series of 
CA-4 analogues that are conformationally cis-restricted. 
Replacement of the ethylene bridge of CA-4 with a β-lactam 
(2-azetidinone) ring provided a rigid scaffold that prevented 
cis-trans isomerisation and maintained a similar spatial 
arrangement between the two phenol rings as the cis-confor-
mation of CA-4 (18). We have already established that some of 
these compounds displayed potent anti-proliferative activity in 
several cancer cell lines and ex vivo patient samples, including 
those displaying multidrug resistance (18-21). However, the 
anti-vascular and anti-metastatic properties of these cis-
restricted analogues remained to be elucidated. The purpose 
Figure 7. CA-432 reduces VEGF-release from human breast adeno carcinoma 
MDA-MB-231 cells. MDA-MB-231 cells were treated with vehicle [0.5% 
(v/v) ethanol] or CA-432 (50 nM) for 6 h in a low serum environment [DMEM 
supplemented with 1% (v/v) FBS]. The conditioned medium was then cen-
trifuged at 400 x g and the supernatants were collected. The concentration 
of VEGF in the supernatants was determined by ELISA. The results were 
normalised for cellular protein concentration and expressed as the percentage 
of VEGF released in the CA-432-treated cells compared to release from 
vehicle-treated control cells (100%). Data represents the mean ± SEM of three 
experiments each carried out in duplicate. A value of P<0.05 was considered 
to be statistically significant (*P<0.05, **P<0.01, ***P<0.001).
Figure 8. CA-432 inhibits the migration of human breast adenocarcinoma 
MDA-MB-231 cells. MDA-MB-231 cells were seeded onto Transwell inserts 
in serum-free medium and placed into companion plates containing 20% 
(v/v) FBS/DMEM and either vehicle [0.5% (v/v) ethanol] or CA-432 (50 nM) 
for 6 h. The upper surfaces of the inserts were swabbed to remove non-
migrated cells. Migrated cells on the underside of the membrane were fixed 
in methanol, stained with Mayer's hematoxylin, dehydrated in methanol and 
mounted on a glass slide. The number of cells in 5 fields at x10 magnification 
was counted. The results were expressed as the percentage of migrated cells 
relative to vehicle-treated control cells (100%) and represent the mean ± SEM 
of three independent experiments. A value of P<0.05 was considered to be 
statistically significant (*P<0.05, **P<0.01, ***P<0.001).
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of this study was to perform a series of in vitro experiments to 
investigate the anti-vascular effects of the compounds directly 
on primary HUVECs and indirectly on the release of pro-
angiogenic VEGF from tumour cells. Finally, we assessed the 
effect of the analogues on one of the critical events involved in 
metastasis, namely, tumour cell migration.
We selected two of the lead cis-restricted CA-4 analogues 
from our previous studies as representative compounds, 
CA-104 and its derivative CA-432, which contained an aryl 
ring substituent at position C-3 of the β-lactam ring (Fig. 1). We 
determined that both analogues potently inhibited HUVEC 
proliferation with IC50 values of 24.9 nM and 4 nM for CA-104 
and CA-432, respectively. These values were either similar or 
lower than those we previously observed in tumour cells such as 
breast carcinoma MCF-7 and MDA-MB-231 cells, promyelo-
cytic leukaemia HL60 cells, chronic myeloid leukaemia K562 
cells and ovarian carcinoma A2780 cells, where IC50 values 
ranged between 17 and 60 nM for CA-104 and 7.5 and 28 nM 
for CA-432 (18-20). The magnitude of response obtained with 
CA-432 was similar to those reported for CA-4 and CA-4P 
which also demonstrated anti-proliferative effects on endo-
thelial cells at lower concentrations than tumour cells (7,37). 
As we previously reported that exposure of normal breast 
epithelial cells to CA-432 induced only a minimal amount of 
cytotoxicity with an IC50 value of greater than 10 mM (19), it 
is interesting that the compounds had such a potent effect on 
non-cancerous endothelial cells. This phenomenon has been 
reported with CA-4P (38) and numerous other microtubule-
targeting agents (22,39) and is postulated to be attributable to 
a variety of mechanisms including enhanced uptake mecha-
nisms in endothelial cells (40) or differences in endothelial 
cell tubulin composition, its post-translational modifications 
or its microtubule-associated proteins (41,42).
The loss in endothelial cell viability following exposure 
to CA-104 and CA-432 was mediated by significant levels of 
G2M arrest and apoptosis which was accompanied by depoly-
merisation of the microtubular networks in HUVECs. Tubulin 
depolymerisation and G2M arrest are typical responses 
observed in tumour cells after exposure to the β-lactam 
analogues (19,20) and also parallels the effects observed with 
CA-4/CA-4P in endothelial cells (43). Studies suggest that the 
type of cell death culminating from CA-4(P)-induced G2M 
arrest varies depending on the conditions and the type of cell. 
Modes of cytotoxicity reported include apoptosis (21,44), 
mitotic catastrophe (45) and autophagy (46,47). Recently we 
found that CA-432 induced mitotic catastrophe in breast carci-
noma cells (48) and autophagy in adenocarcinoma-derived 
colon cancer cells (47). Mitotic arrest prevents the supply of 
endothelial cells required for angiogenesis and cytotoxicity 
leads to the destruction of existing tumour blood vessels, indi-
cating a novel anti-vascular function for the β-lactam CA-4 
derivatives.
Apart from the proliferation and survival of endothelial 
cells, angiogenesis requires several other critical events 
including the migration of endothelial cells into the extra-
cellular matrix and their differentiation into new capillary 
networks (31,49). In addition, stimulation of these angiogenic 
events requires pro-angiogenic or vascular-survival signals 
such as the release of VEGF by tumour cells (50). Interference 
in these processes has been reported in endothelial and 
tumour cells treated with MTAs such as paclitaxel, docetaxel, 
vinblastine and vincristine (28,29,51,52). We established that 
β-lactam CA-4 analogues were capable of directly interfering 
with angiogenic events since they completely abrogated 
VEGF-stimulated HUVEC migration and their spontaneous 
differentiation into capillary-like structures when grown 
on Matrigel, both standard tests for angiogenesis in vitro. 
Furthermore, the derivatives may also indirectly influence 
angiogenesis, as CA-432 significantly reduced the release of 
VEGF from metastatic breast carcinoma MDA-MB-231 cells 
by almost 20%. This is an interesting effect as in addition to its 
angiogenic activity, VEGF can protect endothelial cells from 
apoptosis by stimulating the activation of survival pathways 
such as phosphoinositol-3-kinase (PI3 kinase) and upregula-
tion of anti-apoptotic Bcl-2 and in particular survivin which is 
an important microtubule-binding apoptosis inhibitor involved 
in mitotic spindle regulation (53-56).
These anti-angiogenic findings provided additional 
support to the anti-vascular profile of these CA-4 deriva-
tives and it is interesting to note that these anti-angiogenic 
responses occurred at time points that preceded the onset of 
cytoxicity indicating that the anti-vascular phenotype of these 
compounds cannot solely be attributed to endothelial cell 
death. This effect was also observed with CA-4P which can 
induce complete vascular shutdown within 20 min of drug 
exposure in vivo (57). As drug-induced effects on endothelial 
cell proliferation or cytotoxicity occur too slowly to account 
for this rapid response, it has been postulated that morpho-
logical and functional changes in endothelial cells are more 
likely to cause tumour vascular collapse (30,58). Such changes 
may include rounding-up of cells due to disruption of inter-
phase microtubules leading to rapid remodelling of the actin 
cytoskeleton, assembly of actin stress fibres, actinomyosin 
contractility, formation of focal adhesions, disruption of cell-
cell junctions, including those involving N- and VE-cadherin 
and an increase in monolayer permeability of macromolecules 
(14,59,60). It would therefore, be interesting in the future to 
investigate some of these mechanisms to extend our study 
of the β-lactam CA-4 analogues. It is important to note that 
our initial observations which illustrated inhibition of endo-
thelial cell proliferation and cytotoxicity are still important 
therapeutically, since these mechanisms can play a role in the 
prevention of tumour re-growth in chronic dosing schedules.
Finally, we investigated the effect of CA-432 on one of the 
key events that occurs during metastasis, tumour cell migra-
tion. We chose breast adenocarcinoma MDA-MB-231 cells as 
a model since we previously found that these cells displayed 
good migratory potential (27). We determined that CA-432 
abrogated MDA-MB-231 migration from a low to a high serum 
environment. We previously showed that CA-432 has an IC50 
value of 28.8±0.02 nM in these cells (19), however, similarly 
to endothelial cell migration, interference with tumour cell 
migration preceded cytotoxicity.
In summary, these findings demonstrated novel anti-
vascular and anti-metastatic functions for our cis-restricted 
β-lactam combretastatin A-4 analogues, CA-104 and CA-432. 
Collectively, this report along with our previous studies indi-
cate that these β-lactam CA-4 analogues induced anti-tumour, 
anti-vascular and anti-metastatic events with minimal toxicity 
to normal quiescent cells in vitro. These events are analogous 
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with the functions of CA-4 in vitro. Therefore, these analogues 
should now be considered for further in vivo investigation 
of their anti-tumour and anti-vascular capabilities to further 
evaluate their potential as useful alternatives to the intrinsi-
cally unstable CA-4.
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